XTLB SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Jun 30, 2026

NT 20-F

Form NT 20-F - Notification of inability to timely file Form 20-F

Apr 30, 2026

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 30, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 30, 2024

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 22, 2023

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 30, 2022

News

TYPE

HEADLINE

FILED AT

6-K

XTL Biopharmaceuticals Announces Board Resignation and Nomination of New External Director

Oct 14, 2026

6-K

XTL Biopharmaceuticals Faces Shareholder Derivative Claim Motion Regarding Subsidiary Acquisition

Aug 5, 2026

6-K

XTL Biopharmaceuticals Regains Compliance with Nasdaq Listing Rules

Jul 21, 2026

6-K

XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Become Dedicated Psychedelic Medicine Company

Jun 30, 2026

6-K

XTL Biopharmaceuticals Ltd. Announces Shareholder Approval of Psyga Bio Acquisition and Capital Increase

Jun 29, 2026

6-K

XTL Biopharmaceuticals Ltd. Adjourns Extraordinary General Meeting Due to Lack of Quorum

Jun 22, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 201,500,000 | Warrants amount: 201,500,000 | Warrants exercise price: $4.10

Jun 9, 2021

424B3

3,850,000 American Depositary Shares

Mar 7, 2018

424B5

100,000,000 Ordinary Shares Represented by 1,000,000 American Depositary Shares

Feb 22, 2017

424B5

Per share placement agent fees $ 0.13 Total $ 227,500

Apr 1, 2015

424B5

Registration

Sep 26, 2014

424B3

Registration

Oct 4, 2012

Registrations

TYPE

HEADLINE

FILED AT

POS AM

2,015,000 American Depositary Shares EFFECTIVE

Jun 2, 2021

F-1/A

Registration

Feb 28, 2018

F-1/A

3,850,000 American Depositary Shares

Feb 1, 2018

Form D - Notice of Exempt Offering of Securities - Item 06b

Mar 29, 2017

Form D - Notice of Exempt Offering of Securities - Item 06b

Mar 1, 2017

F-1/A

On April 2, 2015, Green Forest was issued an additional 2,622,647 ordinary shares of Intercure

Nov 7, 2016

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Hillel Fain Osnat (Reporting)

Mar 23, 2026

Segal Niv (Reporting)

Mar 23, 2026

SC 13G/A

SABBY MANAGEMENT, LLC (Filed by)

Jan 5, 2018

SC 13G/A

SABBY MANAGEMENT, LLC (Filed by)

Jan 5, 2018

SC 13G

INTRACOASTAL CAPITAL, LLC (Filed by)

Feb 27, 2017

SC 13G/A

SABBY MANAGEMENT, LLC (Filed by)

Jan 6, 2017

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 8, 2021

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 7, 2018

CORRESP

Form CORRESP - Correspondence

Mar 2, 2018

CORRESP

Form CORRESP - Correspondence

Nov 7, 2016

LETTER

Form UPLOAD - SEC-generated letter

Jan 26, 2016

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 7, 2014

XTL Biopharmaceuticals Ltd. XTLB · SEC Filings